News - Biogen
Oct 30, 2024 · Biogen News Releases and Company Statements. Eisai Completes Rolling Submission to US FDA for LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status.
UCB And Biogen: Dapirolizumab Pegol Meets Primary ... - Markets …
7 hours ago · (RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant ...
Samsung Bioepis, Biogen Get European Commission ... - Markets …
18 hours ago · (RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept. Opuviz ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
12 hours ago · Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug Leqembi’s (lecanemab) sales growth is expected to stay gradual ...
Biogen Announces Positive Topline Results from Study of Higher …
Sep 4, 2024 · Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA; Biogen plans to submit for regulatory approval of this investigational dose regimen; Higher dose nusinersen regimen showed statistically significant improvement compared to a prespecified matched sham control group
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs …
Oct 30, 2024 · (Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new Alzheimer’s treatment.
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo Finance
Find the latest Biogen Inc. (BIIB) stock quote, history, news and other vital information to help you with your stock trading and investing.
Biogen Inc. (BIIB) Latest Stock News & Headlines - Yahoo Finance
Get the latest Biogen Inc. (BIIB) stock news and headlines to help you in your trading and investing decisions.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · CNN — The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the...